



Biotech Daily

Friday July 24, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX DOWN, BIOTECH EVEN: ANTISENSE UP 15%, ACRUX DOWN 13%**
- * **SUNSHINE HEART RESUMES C-PULSE PIVOTAL TRIAL**
- * **COMPUMEDICS EXPECTS REVENUE UP 10%, PROFIT UP 100%**
- * **ACRUX, LILLY AXIRON SALES FALL 14% TO \$211m**
- * **'FREEMAN ROAD' TAKES 5% OF RESAPP**
- * **PHYTOTECH REQUESTS 'MMJ MERGER UPDATE' TRADING HALT**
- * **'LEGAL REASONS' CLOSE DR CHRISTIAN BEHRENBRUCH'S LONG TAIL**

MARKET REPORT

The Australian stock market fell 0.43 percent on Friday July 24, 2015 with the ASX200 down 24.2 points to 5,566.1 points.

Fourteen of the Biotech Daily Top 40 stocks were up, 14 fell, 10 traded unchanged and two were untraded.

Antisense was the best on no news, up 1.4 cents 14.6 percent to 11 cents, with 189,431 shares traded.

Admedus climbed 4.8 percent; Anteo, Impedimed and Prana were up more than three percent; Atcor, Cellmid and Circadian rose more than two percent; Avita, Clinuvel, Neuren, Prima, Tissue Therapies and Viralytics were up more than one percent; with Resmed up 0.5 percent.

Acrux led the falls, down 13 cents or 13.1 percent to 86 cents with 1.5 million shares traded, followed by Analytica down 11.1 percent to 0.8 cents with one million shares traded.

Actinogen lost 9.9 percent; Genetic Technologies shed 6.25 percent; Ellex and Oncosil fell more than four percent; GI Dynamics was down 3.2 percent; Osprey shed 2.6 percent; Biotron and Medical Developments were down more than one percent; with Benitec, Cochlear, CSL, Mesoblast, Sirtex and Starpharma down by less than one percent.

SUNSHINE HEART

Sunshine Heart says its halted 388-patient C-Pulse aorta cuff trial has resumed with the first patient ready to be implanted and all sites to be reactivated by the end August.

Sunshine Heart said that a second patient had been enrolled.

The company said that the prospective, randomized, multi-center, controlled pivotal 'Counter HF' trial was evaluating the safety and efficacy of the C-Pulse system for the treatment of New York Heart Association Class III and ambulatory Class IV heart failure. Sunshine Heart said that the study was temporarily paused in March after the company notified the US Food and Drug Administration of four deaths in the treatment arm of the study, which were adjudicated as "not device or therapy related" and in May, the FDA approved resumption of enrollment (BD: Mar 9, May 27, 2015).

Sunshine Heart chief executive officer Dave Rosa said he was "pleased with the enthusiasm and speed at which sites are being reactivated".

On the Nasdaq last night, Sunshine Heart fell seven US cents or 2.19 percent to \$US3.12 (\$A4.27 equivalent to 2.1 cents prior to departing the ASX) with 115,591 shares traded.

COMPUMEDICS

Compumedics says it expects revenue for the 12 month to June 30, 2015, to be up 10 percent to \$33 million with a net profit after tax of \$1.8 million to \$2.0 million.

Last year, Compumedics posted revenue for the year to June 30, 2014 of \$30,841,000 turning the previous year's loss to a \$909,000 net profit after tax (BD: Aug 27, 2014).

Today, Compumedics said that it had shipped and invoiced about \$33 million in sales, with its core business "on-track with on-going growth trajectory".

The company said its outlook was "strong with further opportunities to accelerate organic growth and value realisation".

Compumedics said that final results would be subject to audit in August, with the Appendix 4E to be released to the ASX on August 26, 2015.

Compumedics was unchanged at 29.5 cents.

ACRUX

Acrux says that Eli Lilly's Axiron sales revenue fell 14.2 percent to \$US155.4 million (\$A211.3 million) for the 12 months to June 30, 2015, compared to June 30, 2014.

For the three months to June 30, 2015, sales revenue fell 31.2 percent from \$US47.1 million to \$32.4 million compared to the three months to June 30, 2014.

The sales data provided by Acrux showed an overall quarter-by-quarter decline in sales since July 2014, following the February 2014 news that the US Food and Drug Administration was investigating cardio-vascular risks in men taking approved testosterone products (BD: Feb 4, 2014).

There have been subsequent announcements that rebut the connection between cardio-vascular risks and testosterone replacement therapy, including studies by the European Medicines Agency and one published in the Mayo Clinic Proceedings which were positive for testosterone for cardiovascular risk (BD: Mar 4, 2015).

Today, Acrux said that its royalties from Eli Lilly for Axiron fell 13.9 percent from \$US22.3 million for the year to June 30, 2014, to \$US19.2 million for the year to June 30, 2015.

Acrux fell 13 cents or 13.1 percent to 86 cents with 1.5 million shares traded.

RESAPP HEALTH (FORMERLY NARHEX LIFE SCIENCES)

Freeman Road Pty Ltd, for The Avenue account, says it has become a substantial shareholder in Resapp with 30,000,000 shares or 5.34 percent.

The substantial shareholder notice was signed by director Tee Yen Ng and gave the address as St George's Terrace, Perth, Western Australia, but did not explain the consideration paid for the shares.

According to the Australian White Pages Freeman Road is located in Maroubra, Sydney, but the LinkedIn page for Trevor Marchant said that he was the owner of Freeman Road Pty Ltd.

Biotech Daily attempted to contact Mr Marchant and Freeman Road but without success at the time of publication.

Resapp fell 0.1 cents or 4.8 percent to two cents with 1.8 million shares traded.

PHYTOTECH MEDICAL

Phytotech has requested a trading halt "pending an update on the company's merger with MMJ Bioscience Inc and a capital raising".

In March, Phytotech said it would acquire the Vancouver, British Columbia-based MMJ Bioscience for up to \$20,685,000 through the issue of up to 68,000,000 Phytotech shares valued at 30.5 cents a share (BD: Mar 24, 2015).

Trading will resume on July 28, 2015 or on an earlier announcement.

Phytotech last traded at 34 cents.

THE LONG TAIL

The Australian listed biotechnology companies commentary website 'The Long Tail' has been closed due to "legal reasons" (BD: Jun 25, 2015).

The website, at www.asxlongtail.com, has commented on a number of companies since its inception on March 18, 2015 and recently apologized to Prima's head of investor relations Stuart Roberts, for one of his posts.

Under the heading 'I'll be back' with an image of Arnold Schwarzenegger as The Terminator, the website's author Dr Christian Behrenbruch said he would "temporarily take this site down".

"I got a little bit of heat for some of my posts," Dr Behrenbruch said.

Dr Behrenbruch told Biotech Daily he could not comment on the shut-down.

"I have been compelled to shut my website down for legal reasons," Dr Behrenbruch told Biotech Daily.